**ORIGINAL ARTICLE**

# CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis

David Baker[1*], Amy MacDougall[2], Angray S. Kang[1,3], Klaus Schmierer[1,5], Gavin Giovannoni[1,5], Ruth Dobson[4,5, *]

[1]The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom

[2]Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom

[3]Centre for Oral Immunobiology and Regenerative Medicine, Dental Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

[4]Preventive Neurology Unit, Wolfson Institute of Population Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom

[5]Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom

*__Correspondence__:

Dr Ruth Dobson. Preventive Neurology Unit, Wolfson Institute of Population Health, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ. Tel: +44 207 882 6463. Email Ruth.Dobson@qmul.ac.uk. ORCID: 0000-0002-2993-585X

Professor David Baker, The Blizard Institute, Queen Mary University of London, 4 Newark Street, London, E1 2AT. Phone: +44 207 882 2485. Email: david.baker@qmul.ac.uk . ORCID: 0000-0002-8872-8711

**MedRXiv:** doi: https://medrxiv.org/cgi/content/short/2021.09.26.21264023v1

**Highlights**

- Clinical trial data was interrogated to determine the frequency of 1-3% B cell repopulation over 12-18 months

- Few people repopulate after standard 6 monthly ocrelizumab dosing, but an extended dosing interval could allow many more people to repopulate B cells.

- CD19+ B cells rapidly repopulated after cladribine and alemtuzumab treatment.

**Abstract**

**Background**: Ocrelizumab maintains B-cell depletion via six-monthly dosing. Whilst this controls relapsing multiple sclerosis, it also inhibits seroconversion following SARS-CoV-2 vaccination unlike that seen following alemtuzumab and cladribine treatment. Emerging reports suggest that 1-3% B-cell repopulation facilitates seroconversion after CD20-depletion.

**Objective:** To determine the frequency of B-cell repopulation levels during and after ocrelizumab treatment.

**Methods**: Relapse data, lymphocyte and CD19 B-cell numbers were obtained following requests to clinical trial data-repositories. Information was extracted from the phase II ocrelizumab extension (NCT00676715) trial and the phase III cladribine tablet (NCT00213135) and alemtuzumab (NCT00530348/NCT00548405) trials obtained clinical trial data requests

**Results:** Only 3-5% of people with MS exhibit 1% B-cells at 6 months after the last infusion following 3-4 cycles of ocrelizumab, compared to 50-55% at 9 months, and 85-90% at 12 months. During this time relapses occurred at consistent disease-breakthrough rates compared to people during standard therapy. In contrast most people (90-100%) exhibited more than 1% B-cells during treatment with either cladribine or alemtuzumab.

**Conclusions.** Most people demonstrate B cell repletion within 3 months of the last treatment of alemtuzumab and cladribine. However, few people repopulate peripheral B-cells with standard ocrelizumab dosing. Controlled studies are warranted to examine a view that delaying the dosing interval by 3-6 months may allow more people to potentially seroconvert after vaccination.

**Keywords: Multiple sclerosis, ocrelizumab, rituximab, CD20, alemtuzumab, cladribine**

**Background**

Therapeutic B cell targeting antibodies such as ocrelizumab and rituximab are used as a maintenance treatment for the control of multiple sclerosis (MS). Their efficacy may relate to either the direct long-term depletion of memory B cells and development of regulatory B cells within the regenerating CD19 population [1] or indirectly through the blockade of T cell activity [2]. Six-monthly dosing schedules, as used in MS, maintain continuous CD20+ B cell suppression in the periphery.

Given the blunted antibody response to other vaccines [3] it is not surprising that CD20-depleting antibodies, notably rituximab and ocrelizumab, repeatedly and consistently appear to induce poor seroconversion following natural infection with SARS-CoV-2 [4, 5]. Furthermore seroconversion in CD20-depleted, COVID-19 vaccinated individuals is universally poor [6-8]. In contrast many people treated with cladribine tablets and alemtuzumab after therapy show seroconversion following COVID-19 vaccination [6-8].

Whilst protection from MS may result from depletion of memory B cells [9], seroconversion has been attributed to immature/naïve B cell repletion and occurs following the development of 1-3% B cell repopulation [10-13]. However, the frequency of people achieving 1% B cell repletion at specific time intervals following ocrelizumab dosing is largely unknown [14]. We hypothesised that it may require an extended-dose interval to achieve 1% peripheral B cell repopulation in at least 50%, given the median time of 60-72 weeks for B cells to recover to the lower limit of normal (80 cells/μl) following ocrelizumab infusion [1].

**Methods**

Anonymised trial data was provided by the trial sponsors following an independent panel review of the data analysis plans at clinincaltrialsdatarequest.com of the data analysis plans (#5836. #11529). The trials were performed in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki. All patients provided written informed consent. This analysis was not subject to further ethical review.

Access to the Roche/Genentech phase II ocrelizumab extension trial in (NCT00676715) was requested (#5984) and supplied under contract by the Vivli, Inc managed portal. Data from people with relapsing MS who had received three or four 6-monthly cycles of 600mg ocrelizumab prior to an 18 month treatment-free observation period were used. Lymphocyte and CD19+ numbers were collected during the 18 month treatment-free follow up period [1]. Trial data were interrogated using R software. A mixed effects logistic regression was fitted with a binary marker for CD19 count above 1% of total lymphocyte count as outcome. Repeated measures for each individual were included from last treatment to 18 months post-treatment. Included as covariates were: baseline body mass Index (BMI); time in years; quadratic term for time; arm of trial.

Lymphocyte numbers and CD19 peripheral counts information from the phase III (CLARITY) clinical trial of oral cladribine (NCT00213135) was supplied by the European Medicines Agency following a Freedom of Information request [15]. Data relating to the 3.5mg/kg licenced dose was extracted. In addition, access to the Sanofi/Genzyme phase III alemtuzumab CARE-MS1 (NCT00530348) and

CARE-MS-2 (NCT00548405) trials [16] was requested (#11529) and supplied under contract by the clinicalstudydatarequest.com portal. Lymphocyte and peripheral blood CD19 B cell data, relating to the 12mg licenced dose, were extracted from the CARE-MS trials.

**Results**

3-5% of people had repopulated to 1-3% B cell count by the end of the standard ocrelizumab dose interval of 6 months [Table 1]. At 9 months following treatment cessation there was 50-55% B cell repopulation, and at 12 months 85-90% B cells had repopulated to at least 1% B cells [Table 1, Figure 1]. During the treatment-free observation period between week 96 to week 108 there were 9 relapses (3 cycles) and 4 relapses in people who received 4 cycles of treatment [Table 1]. This frequency of disease breakthrough was comparable to 9/99 people relapsing (3 cycles) and 6/49 (4 cycles) during week 72-96 period on-standard treatment schedule (Table 1, Supplementary Figure 1 & 2). There was again evidence that baseline BMI was associated with CD19 re-population. For each increase in BMI of 5 units, the odds of having CD19 count above 1% of total lymphocyte count increased by 2.50 (95% confidence interval: 1.45-5.20; p=0.003) as suggested previously [17, 18].

In contrast to the persistent B cell depletion following ocrelizumab treatment (Table 1), the majority of people treated with either cladribine tablets (Table 2) or alemtuzumab (Table 3) maintained 1% B cell levels and also developed at least 10-20 CD19 B cells/μl, in contrast to levels detected after ocrelizumab (Table 1-3). B cell depletion was most marked about after the second set of treatments during the cladribine treatment cycle (Table 2). Depletion was evident within the first month of alemtuzumab treatment followed by rapid B cell repopulation (Table 3)

**Discussion**

During the COVID-19 pandemic ocrelizumab infusions were delayed by 1-3 months, with no apparent major rebound in disease activity, suggesting the potential safety of an delayed-dosing scheme [19-22]. The importance of mounting a sterilising response relates not only to clinical severity of infection, but also that immunosuppressed individuals may harbour prolonged SARS-CoV-2 infection allowing serial mutations to develop, impacting on infectivity and immune escape [23, 24].

Given the importance of neutralizing antibody responses [23], and the finding that protective SARS-CoV-2 antibody titres subside over time, COVID-19 breakthrough can and will occur. This is already seen in vaccinated, healthy individuals [25]. This is further complicated as SARS-CoV-2 variants appear that have increased infectivity and immune-escape features requiring more antibody to neutralize infection, compared to the initial SAR-CoV-2 strain [26]. As CD20-treated individuals often produce lower titre antibody responses than untreated controls [6-8], they are potentially in particular need of effective booster (third cycle) vaccinations to limit infection. However, it is clear that the majority of CD20-depleted individuals, even in those with low antibody titres, generate robust CD4 and CD8 anti-viral T cell responses following the initial vaccination that can provide protective immunity following infection [10,27-29]. Whilst booster vaccines may increase seroconversion and augment existing immune responses in some immunocompromised people, CD20 depletion can still inhibit booster responses as already seen in MS and other conditions using rituximab [30-34], particularly in those who failed to seroconvert after two vaccine doses [33,34].

A solution may be to provide a high-titre antibody response through monoclonal antibody cocktails or use of convalescent sera in high-risk individuals [35]. Furthermore, anti-viral agents are being developed [36], which could help augment the protective effect of any immunity in immunosuppressed individuals. It remains to be seen to what extent vaccine-induced T cell responses and biological and chemical anti-viral agents are sufficient to protect CD20-depleted individuals. However, maximising the chance of an effective response to vaccination in immunosuppressed people should be a priority, if it is safe to do so. It is evident that CD19 B cells recover rapidly following cladribine and alemtuzumab [14, 15] and this is probably consistent with a robust COVID-vaccine response in most people if vaccination in undertaken once immune-reconstitution occurs [6-8]. However based on the B cell repopulation kinetics and poor vaccine response, one could argue that delaying treatment for a short period to facilitate the most-effective booster programme possible may be a justifiable risk, based on this uncontrolled trial data, which suggested comparable annualised relapse rate and disease breakthrough during the treatment-delayed period to that seen in other studies during continuous treatment [1], and notably the experience with treatment delays during the COVID-19 pandemic [19-22]. However, unless controlled-studies are conducted to demonstrate safety, it may be too late to inform on and optimize the next stage of vaccination process/COVID-19 control in ocrelizumab-immunosuppressed people with multiple sclerosis.

**Funding.** This research received no specific funding.

**Acknowledgments**: This publication is in part based on research using data from data contributors Roche and Sanofi that has been made available through Vivli, Inc and Clinicalstudydatarequest.com. Clinicalstudydatarequest.com and Vivli have not contributed to or approved, and are not in any way responsible for, the contents of this publication. Data analysis, interpretation and conclusions made are independent from Roche, Sanofi and Merck.

**Conflicts of Interest:** DB, KS, GG RB, have received compensation for consultancy/educational activity from Roche/Genentech, Merck, and/or Sanofi/Genzyme who manufacture COVID-19 and MS drugs discussed in this study. These were not involved in the content or the decision to publish. AM, AK have nothing relevant to declare. Although considered irrelevant DB, KS, GG, RB have received compensation for consultancy/educational activity from all companies manufacturing licenced disease modifying agents in the MS space.

**References**

1, Baker D, Pryce G, James LK, Marta M, Schmierer K. The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis. Mult Scler Relat Disord. 2020; 44a:102279.

2. Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, et al. Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis. Cell. 2018; 175:85-100.e23.

3.Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, Schmierer K, Giovannoni G, Amor S. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol. 2020; 202:149-161.

4. Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020; 77:1079-1088.

5. Sormani MP, Schiavetti I, Landi D, Carmisciano L, De Rossi N et al. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. Mult Scler. 2021a; Jul 30:13524585211035318.

6. Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012835.

7. Sormani MP, Inglese M, Schiavetti I, Carmisciano L, Laroni A, et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine 2021; 72: 103581.

8.Tallantyre EC, Vickaryous N, Anderson V, Asardag AN, Baker D, et al. COVID-19 vaccine response in people with multiple sclerosis. Ann Neurol. 2021 Oct 22. doi: 10.1002/ana.26251.

9. Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine. 2017a; 16:41-50.

10. Madelon N, Lauper K, Breville G, Royo IS, Goldstein R, et al. Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccines. Clin Infect Dis. 2021 Nov 17:ciab954. doi: 10.1093/cid/ciab954.

11.Mrak D, Tobudic S, Koblischke M, Graninger M, Radner H et al. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis. 2021; 80:1345.

12. Stefanski AL, Rincon-Arevalo H, Schrezenmeier E, Karberg K, Szelinski F, et al. B cell numbers predict humoral and cellular response upon SARS-CoV-2 vaccination among patients treated with rituximab. MedRxiv 2021. doi: https://doi.org/10.1101/ 2021.07.19.21260803

13. Disanto G, Sacco R, Bernasconi E, Martinetti G, Keller F, et al. Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to SARS-CoV-2 vaccines in patients with multiple sclerosis. JAMA Neurol. 2021. 23: e213609.

14. Gibiansky E, Petry C, Mercier F, Günther A, Herman A, Kappos L, et al. Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. Br J Clin Pharmacol. 2021; 87:2511-2520.

15. Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, et al. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm. 2017; 4:e360.

16. Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. JAMA Neurol. 2017; 74:961-969.

17. Kletzl H, Gibiansky E, Petry C, Mercier F, Guenther A, Wang Q, Model F, Kappos L, Hauser S Pharmacokinetics, pharmacodynamics and exposure-response analyses of ocrelizumab in patients with multiple sclerosis (N4.001). Neurology 2019; 92 (Suppl 15) N4.001

18. Signoriello E, Bonavita S, Di Pietro A, Abbadessa G, Rossi F, et al. BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab. Mult Scler Relat Disord. 2020;43:102186

19. Maarouf A, Rico A, Boutiere C, Perriguey M, Demortiere S et al. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? Neurol Neuroimmunol Neuroinflamm. 2020; 7:e825.

20. Rolfes L, Pawlitzki M, Pfeuffer S, Nelke C, Lux A et al. Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol Neuroimmunol Neuroinflamm. 2021;8:e1035.

21. van Lierop ZY, Toorop AA, van Ballegoij WJ, Olde Dubbelink TB, Strijbis EM, et al. Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. Mult Scler. 2021 Jul 9:13524585211028833.

22. Baker D, MacDougall A, Kang AS, Schmierer K, Giovannoni G et al. Seroconversion following COVID-19 vaccination: Can we optimize protective response in CD20-treated individuals? Clin Exp Immunol 2021; uxab015, https://doi.org/10.1093/cei/uxab015.

23. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205-1211

24. Corey L, Beyrer C, Cohen MS, Michael NL, Bedford T, Rolland M. SARS-CoV-2 variants in patients with immunosuppression. N Engl J Med. 2021;385:562-566

25. Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet. 2021; 398:385-387.

26. Uriu K, Kimura I, Shirakawa K, Takaori-Kondo A, Nakada TA, et al. Genotype to phenotype Japan (g2p-japan) consortium. neutralization of the SARS-CoV-2 mu variant by convalescent and vaccine serum. N Engl J Med. 2021 Nov 3:NEJMc2114706].

27. Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021;27:1990-2001.

28. Gadani SP, Reyes-Mantilla M, Jank L, Harris S, Douglas M, Smith MD, Calabresi PA, Mowry EM, Fitzgerald KC, Bhargava P. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. EBioMedicine. 2021;73:103636.

29. Brill L, Rechtman A, Zveik O, Haham N, Oiknine-Djian E et al. Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab. JAMA Neurol. 2021 Sep 23:e213599.

30. Connolly CM, Teles M, Frey S, Boyarsky BJ, Alejo JL, et al. Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series. Ann Rheum Dis. 2021 Sep 7:annrheumdis-2021-221206. doi: 10.1136/annrheumdis-2021-221206

31.Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ et al. Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies Cancer cell 2021; 39:1297-1299.

32. Re D, Seitz-Polski B, Carles M, Brglez V, Graça D et al. Humoral and cellular responses after a third dose of BNT162b2 vaccine in patients treated for lymphoid malignancies *Medrxiv* 2021. doi: https://doi.org/10.1101/ 2021.07.18.21260669.

33. König M, Torgauten HM, Overas MH, Chopra A, Lorentzen AR et al. Efficacy and safety of a third SARS-CoV-2 vaccination in multiple sclerosis vaccine non-responders. *MedRxiv*. 2021. https://doi.org/10.1101/ 2021.10.15.21264977.

34. Sidler, D., Born, A., Schietzel, S., Horn MP, Aeberli D et al. Longitudinal analysis of antibody trajectories and humoral responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy (RituxiVac 2.0). MedRxiv 2021 doi: 10.1101/2021.11.19.21266572, R

35. Hurt AC, Wheatley AK. Neutralizing antibody therapeutics for COVID-19. Viruses. 2021; 13:628.

36. Lee CC, Hsieh CC, Ko WC. Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent. Antibiotic. 2021; 10:1294.

**Table 1.** *CD19 B cell repletion and relapse rates after repeated ocrelizumab infusions*

| Treatment | Time from Treatment Onset | Number of CD19+ cells of total lymphocytes/total | | |
|---|---|---|---|---|
| | | 1% B cells | 2% B cells | 3% B cells |
| Ocrelizumab 3 cycles | 6 months | 4/81 ( 5%) | 3/81 ( 4%) | 2/81 ( 2%) |
| | 9 months | 43/80 (54%) | 30/80 (38%) | 22/80 (28%) |
| | 12 months | 76/84 (90%) | 68/84 (81%) | 57/84 (68%) |
| | 15 months | 44/48 (92%) | 41/48 (85%) | 35/48 (73%) |
| | 18 months | 29/31 (93%) | 25/31 (81%) | 22/31 (71%) |
| Ocrelizumab 4 cycles | 6 months | 1/39 ( 3%) | 1/39 ( 3%) | 1/39 ( 3%) |
| | 9 months | 20/40 (50%) | 11/40 (28%) | 8/40 (20%) |
| | 12 months | 35/41 (85%) | 25/41 (61%) | 19/41 (46%) |
| | 15 months | 26/28 (93%) | 20/28 (71%) | 14/28 (50%) |
| | 18 months | 26/28 (93%) | 22/28 (79%) | 20/28 (71%) |

| Treatment | Time from Treatment | Number of PwMS with the indicated number of CD19+ B cells | | | | |
|---|---|---|---|---|---|---|
| | | > 1 cell/µl | >5 cells/µl | >10cells/µl | >20 cells/µl | >30 cells/µl |
| Ocrelizumab 3 cycles | 0 months | 68/92 (74%) | 25/92 (27%) | 13/92 (14%) | 8/92 (9%) | 8/92 (9%) |
| | 6 months | 67/84 (80%) | 20/84 (24%) | 6/84 (7%) | 4/84 (5%) | 4/84 (5%) |
| | 9 months | 77/83 (93%) | 64/83 (77%) | 51/83 (61%) | 41/83 (49%) | 30/83 (36%) |
| | 12 months | 84/84 (100%) | 81/84 (96%) | 76/84 (90%) | 75/84 (89%) | 70/84 (83%) |
| | 15 months | 49/49 (100%) | 47/49 (96%) | 46/49 (94%) | 46/49 (94%) | 42/49 (85%) |
| | 18 months | 37/37 (100%) | 36/37 (97%) | 34/37 (92%) | 31/37 (84%) | 30/37 (81%) |
| Ocrelizumab 4 cycles | 0 months | 36/46 (78%) | 13/46 (28%) | 5/46 (11%) | 0/46 (0%) | 0/46 (0%) |
| | 6 months | 31/39 (79%) | 7/39 (18%) | 1/39 (3%) | 1/39 (3%) | 1/39 (3%) |
| | 9 months | 42/43 (98%) | 34/43 (79%) | 24/43 (56%) | 19/43 (44%) | 13/43 (30%) |
| | 12 months | 41/41 (100%) | 39/41 (95%) | 38/41 (93%) | 31/41 (76%) | 24/41 (59%) |
| | 15 months | 29/29 (100%) | 29/29 (100%) | 28/29 (97%) | 25/29 (86%) | 22/29 (76%) |
| | 18 months | 28/28 (100%) | 28/28 (100%) | 28/28 (100%) | 26/28 (93%) | 24/28 (86%) |

| Treatment | Time from Last Infusion | No.Relapse/Total | Relapse rate/yr. |
|---|---|---|---|
| Ocrelizumab 3 cycles | 0-6 months | 9/99 | 0.18 |
| | 6-9 months | 4/85 | 0.19 |
| | 9-12 months | 5/72 | 0.28 |
| | 12-15 months | 3/77 | 0.16 |
| | 15-18 months | 0/80 | 0.00 |
| | Time from Last Infusion | No.Relapse/Total | Relapse rate/yr. |
| Ocrelizumab 4 cycles | 0-6 months | 6/49 | 0.24 |
| | 6-9 months | 3/43 | 0.28 |
| | 9-12 months | 1/33 | 0.12 |
| | 12-15 months | 1/38 | 0.11 |
| | 15-18 months | 5/42 | 0.48 |

Individuals received 600mg ocrelizumab Q24W for 3 or 4 cycles followed an 18 month treatment-free period. The data was extracted from the phase II ocrelizumab extension study[1] supplied, via the www.vivli.org portal, using R software. The last ocrelizumab infusion occurred around 72 weeks. Data capture was scheduled for weeks 96 (6 months), 108 (9 months), 120 (12months), 132 (15 months) and 144 (18 months). The results represent the approximate time from the last infusion (months) and report the frequency of people reaching 1%, 2% or 3% CD19 of total lymphocyte count or the absolute number of cells/µl following either 4 infusion cycles (0-72 weeks) of ocrelizumab or 3 ocrelizumab infusion cycles (24-72 weeks) after either placebo or beta interferon (0-24 weeks). At 24 weeks after last infusion 4/123 pwMS had over 40cells/µl. Relapses were ascribed to approximate times following the last infusion and the unadjusted, annualized relapse rate were calculated. PwMS people with multiple sclerosis.

**Table 2.** *CD19 B cell repletion following administration of cladribine tablets*

| Treatment | Time from Treatment Onset | Number of % CD19 B cells of total lymphocytes/total | | |
|---|---|---|---|---|
| | | 1% B cells | 2% B cells | 3% B cells |
| Cladribine cycle1 | 0 weeks | 82/82 (100%) | 82/82 (100%) | 81/82 (99%) |
| | 5 weeks | 75/76 (99%) | 73/76 (96%) | 61/76 (80%) |
| | 9 weeks | 65/72 (90%) | 42/72 (58%) | 26/72 (36%) |
| | 13 weeks | 70/72 (97%) | 62/72 (86%) | 47/72 (51%) |
| | 16 weeks | 76/77 (99%) | 70/77 (91%) | 60/77 (78%) |
| | 24 weeks | 77/77 (100%) | 75/77 (97%) | 70/77 (91%) |

| Treatment | Time from Treatment | Number of PwMS with indicated number of CD19+ B cells | | | |
|---|---|---|---|---|---|
| | | >5 cells µl | >10cells/µl | >20 cells/µl | >30 cells/µl |
| Cladribine cycle 1 | 0 weeks | 81/81 (100% | 81/81 (100% | 81/81 (100% | 81/81 (100% |
| | 5 weeks | 76/76 (100%) | 73/76 (96%) | 63/76 (83%) | 60/76 (79%) |
| | 9 weeks | 68/72 (94%) | 51/72 (71%) | 31/72 (43%) | 21/72 (29%) |
| | 13 weeks | 74/76 (97%) | 71/76 (93%) | 59/76 (78%) | 42/76 (55%) |
| | 16 weeks | 77/77 (100%) | 74/77 (96%) | 66/77 (86%) | 59/77 (77%) |
| | 24 weeks | 78/78 (100%) | 77/78 (99%) | 74/78 (95%) | 66/78 (84%) |

Individuals received 1.75mg/kg cladribine tablets over 1 week and this was repeated one month later. The information was extracted from the phase III trial data supplied by the European Medicines Agency [14].The second cycle of cladribine was not adjusted to lymphopenia as occurs in the licenced dosing schedule and is therefore not shown. The results represent the approximate time from the onset of treatment and report the frequency of people reaching 1%, 2% or 3% CD19 of total lymphocyte count or the number of cases with absolute number of peripheral blood CD19+ B cells above the cell count. The data was calculated from B cell numbers reported as cells/µl and lymphocyte data reported to cells $x10^9$/l to two decimal places. PwMS people with multiple sclerosis

**Table 3.** *CD19 B cell repletion following alemtuzumab infusion*

| Treatment | Time from last infusion | Number of % CD19 B cells of total lymphocytes/total analysed | | |
|---|---|---|---|---|
| | | 1% B cells | 2% B cells | 3% B cells |
| Alemtuzumab cycle1 | 0 weeks | 362/362 (100%) | 362/362 (100%) | 362/362 (100%) |
| | 1 month | 365/365 (100%) | 214/365 (59%) | 156/365 (43%) |
| | 3 months | 368/368 (100%) | 368/368 (100%) | 368/368 (100%) |
| | 6 months | 372/372 (100%) | 372/372 (100%) | 372/372 (100%) |
| Alemtuzumab cycle 2 | 1 months | 367/367 (100%) | 292/367 (80%) | 234/367 (64%) |
| | 3 months | 367/367 (100%) | 366/367 (100%) | 366/367 (100%) |
| | 6 months | 374/374 (100%) | 374/374 (100%) | 374/374 (100%) |
| Treatment | Time from last infusion | Number of PwMS with indicated number of CD19+ B cells | | |
| | | ≥10 cells/μl | ≥20 cells/μl | ≥30 cells/μl |
| Alemtuzumab cycle 1 | 0 weeks | Insufficient data to calculate | 362/362 (100%) | 362/362 (100%) |
| | 1 month | | 365/365 (100%) | 23/365 (6%) |
| | 3 months | | 368/368(100%) | 368/368 (100%) |
| | 6 months | | 372/372 (100%) | 372/373 (100%) |
| Alemtuzumab Cycle 2 | 1 months | | 367/367 (100%) | 71/267 (19%) |
| | 3 months | | 367/367 (100%) | 360/367 (98%) |
| | 6 months | | 374/374 (100%) | 372/374 (99%) |

Individuals received 60mg alemtuzumab (cycle 1) and 36mg alemtuzumab (cycle 2) twelve months later. The information was extracted from the phase III CARE-MS 1 (treatment naïve) and the CARE-MS 2 (prior beta interferon treatment) trial data [15] supplied by the manufacturer via the clinicalstudydatarequest.com portal. The results represent the approximate time from the onset of treatment and report the frequency of people reaching 1%, 2% or 3% CD19 of total lymphocyte count or the number of cases with an absolute number of peripheral blood CD19+ B cells above the cell number shown. These were reported to two decimal places reported as a percentage of lymphocytes or absolute number as cells $x10^9$/l. The minimum number of cells reported was therefore 20 cells/μl. The percentage lymphocytes was reported to no decimal places. PwMS people with multiple sclerosis

**Figure 1**. *Individual blood levels of B cells following ocrelizumab treatment*




People with relapsing MS were treated with 600mg ocrelizumab from week 0-72 or 24-72. The data was extracted from the phase II ocrelizumab extension study [1] supplied via the Vivli Inc platform using R software. The results represent the percentage CD19 count compared to total lymphocyte count repopulation over time. The 1% (dash dot), 2% (dash) and 3 % (dot) CD19 B cell levels are indicated.

**SUPPLEMENTARY DATA**

**Figure 1S.** *Individual peripheral blood CD19 levels and relapse activity*




People with relapsing MS were treated with either placebo or 600mg ocrelizumab (OCZ) from week 0 and all received 6 monthly 600mg ocrelizumab from week 24-72. People were followed to week 144. The data was extracted from the phase II ocrelizumab extension study [1] supplied via the www.vivli.org portal using R software. The results represent the absolute CD19+ peripheral blood cell counts (circle. cells/µl) and relapse disease activity (dashed line). Relapses were not associated with changes in peripheral blood B cell levels.

**Figure 2S.** *Individual peripheral blood memory B cell and relapse activity*




People with relapsing MS were treated with either placebo or 600mg ocrelizumab (OCZ) from week 0 and all received 6 monthly 600mg ocrelizumab from week 24-72. People were followed to week 144. The data was extracted from the phase II ocrelizumab extension study [1] supplied via the www.vivli.org portal using R software. The results represent the absolute CD19+, CD27+ peripheral blood memory B cell counts (circle. cells/µl) and relapse disease activity (dashed line).